APVMA LIMITED USE PERMIT 13512- BUPARVAQUONE & PRIMAQUINE PHOSPHATE/ CALVES/ TICK FEVER VACCINE

Land: Australia

Språk: engelsk

Kilde: APVMA (Australian Pesticides and Veterinary Medicines Authority)

Aktiv ingrediens:

buparvaquone(50mg/mL)+primaquine phosphate(50mg/mL)

Tilgjengelig fra:

APVMA PERMIT

INN (International Name):

buparvaquone(50mg/mL)+primaquine phosphate(50mg/mL)

Produsert av:

TICK FEVER CENTRE

Terapeutisk område:

antiprotozoal

Produkt oppsummering:

For tick fever research on calves.

Autorisasjon status:

Registered and available

Autorisasjon dato:

2012-06-30

Informasjon til brukeren

PER13512
Permit Version 1
Page 1 of 3 PERMIT TO ALLOW POSSESSION, SUPPLY AND USE OF TWO UNREGISTERED
VETERINARY CHEMICAL PRODUCTS
PERMIT NUMBER -PER13512
This permit is issued to the Permit Holder in response to an
application granted by the APVMA
under section 112 of the Agvet Codes of the jurisdictions set out
below. This permit allows a
Supplier (as indicated) to possess The Products for the purposes of
supply and to supply The
Products to a person who can use The Products under permit. This
permit also allows a person,
as stipulated below, to use The Products in the manner specified in
this permit in the designated
jurisdictions. This permit also allows the Permit Holder, the Supplier
(if not one and the same)
and any person stipulated below to claim that The Products can be used
in the manner specified
in this permit. If this permit were not issued, supply of The Products
as specified below would
constitute an offence under section 78 of the Agvet Code.
THIS PERMIT IS IN FORCE FROM 30 JUNE 2012 TO 30 JUNE 2017.
PERMIT HOLDER:
Tick Fever Centre
Queensland Department of Agriculture, Fisheries and Forestry
280 Grindle Road
WACOL QLD 4076.
PERSONS AUTHORISED BY THIS PERMIT TO SUPPLY AND MAKE CLAIMS:
Tick Fever Centre
Queensland Department of Agriculture, Fisheries and Forestry
280 Grindle Road
WACOL QLD 4076.
PERSONS AUTHORISED BY THIS PERMIT TO USE THE PRODUCTS:
Research staff of the Tick Fever Centre are authorised to use the
products, under veterinary
supervision.
PRODUCTS TO BE USED:
Butalex containing 50 mg/mL buparvaquone as the only active
constituent.
Primaquine containing 50 mg/mL primaquine phosphate as the only active
constituent.
PER13512
Permit Version 1
Page 2 of 3
DIRECTIONS FOR USE:
Use only for the treatment of theileriosis in splenectomised calves as
described below.
ANIMAL PURPOSE DOSE
Calves Tick Fever Research 2.5 mg buparvaquone/kg intramuscularly
administered in 2 doses 48 hours apart.
2 mg primaquine phosphate /kg
subcutaneously once as a ‘knock down’
treatment.
When administered in c